Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

الصحة النفسية: دعوة للشراكة مع المؤسسات العامة والأكاديميا ومنظمات المجتمع المدني


The Ministry of Public Health’s Vision is that of “An equitable health system that identifies and addresses the key determinants of physical and mental health and promotes, develops and sustains the highest attainable physical and mental health status of all Lebanese.”
 
To achieve this vision, the Ministry aims at building and sustaining an effective, high impact organization and works in partnership with all stakeholders, following good governance principles, to develop its institutional capacity for effective stewardship of the health sector, to ensure the promotion of better health and the provision of equitable, efficient and quality health services, in both public and private sector, that respond to people’s needs, with particular emphasis on the disadvantaged and vulnerable populations, thereby contributing to sustainable development of the country.
 
The Ministry thereby adopts an open-network collaborative type of governance for the health system based on an inter-sectoral approach and cooperates with other ministries, the private sector and the Civil Society in order to achieve its goals. As emphasized by the Director-General of Health, Professor Walid Ammar, during his address as the Laureat of the renewed Shousha Foundation Prize by the WHO for his significant contribution to public health in Lebanon:

“If I should attribute progress to one single characteristic of the health system, I would say: innovative governance. The most difficult leadership is that of getting things done by a multitude of stakeholders with different agenda, interests, and beliefs. The Lebanese society is plural and diverse by its different confessions and political groups, a strong private-for-profit sector and an active civil society with powerful NGOs. Considering the very limited resources and weak authority of the public sector, the challenge is how to make all these partners work together to achieve national health goals. The answer is to find a non-hierarchical governance structure, that replaces control and command leadership, by a collaborative leadership to achieve common goals through an open networking type of governance”. 

The MOPH promotes partnership with not only governmental entities but also non-governmental entities to achieve national goals through innovative governance mechanisms, such as inter-ministerial collaboration to promote inter-sectoral action, public-private partnership to jointly address national system challenges such a fragmentation of health financing and service provision, partnerships with  academia, including University Hospitals, to strengthen health systems and implementation research in order to further improve health services and ensure alignment of efforts towards achieving national health goals.
    2
    ...
ATC Name B/G Ingredients Dosage Form Price
B01AF01 RIXALTA 20 G Rivaroxaban - 20mg 20mg Tablet, film coated 1,164,664 L.L
B01AF01 RIBAVAN G Rivaroxaban - 10mg 10mg Tablet, film coated 959,888 L.L
B01AF01 RIXALTA 10 G Rivaroxaban - 10mg 10mg Tablet, film coated 671,921 L.L
B02BD02 RECOFACT VIII BioTech Moroctocog alfa - 500IU 500IU Injectable powder for solution+diluent 12,049,005 L.L
B02BD04 REFIXIA BioTech Nonacog beta pegol (factor IX) - 500IU 500IU Injectable powder for solution+solvent 76,080,435 L.L
B02BD04 REFIXIA BioTech Nonacog beta pegol (factor IX) - 1000IU 1000IU Injectable powder for solution+solvent 149,006,584 L.L
B02BD04 REFIXIA BioTech Nonacog beta pegol (factor IX) - 2000IU 2000IU Injectable powder for solution+solvent 298,171,597 L.L
B02BD08 RECOFACT VII BioTech Eptacog alfa (activated) recombinant - 1.2mg 1.2mg Injectable powder for solution+diluent 47,533,131 L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 50mg 50mg Tablet, film coated L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 25mg 25mg Tablet, film coated 75,701,015 L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 50mg 50mg Tablet, film coated 151,399,262 L.L
B03XA06 REBLOZYL BioTech Luspatarcept - 25mg 25mg Injectable powder for solution 125,960,784 L.L
B03XA06 REBLOZYL BioTech Luspatercept - 75mg 75mg Injectable powder for solution 377,881,318 L.L
B05BB01 RINGER'S INJECTION USP G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 199,957 L.L
B05BB01 RINGER'S INJECTION, USP G Calcium chloride, 2H2O - 0.33g/l, Potassium chloride - 0.3g/l, Sodium chloride - 8.6g/l Injectable solution 189,615 L.L
B05BB01 RINGER INJECTION G Sodium chloride - 0.86g/100ml, Calcium Chloride Dihydrate - 0.033g/100ml, Potassium chloride - 0.03g/100ml Injectable solution 204,554 L.L
B05BB01 RINGER'S INJECTION USP G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 129,934 L.L
B05BB01 RINGER'S INJECTION USP G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 205,933 L.L
B05BB01 RINGER'S INJECTION USP G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 224,565 L.L
B05BB01 RINGER'S INJECTION, USP G Calcium chloride, 2H2O - 0.33g/l, Potassium chloride - 0.3g/l, Sodium chloride - 8.6g/l Injectable solution 204,554 L.L
B05BB01 RINGER'S INJECTION, USP G Calcium chloride, 2H2O - 0.33g/l, Potassium chloride - 0.3g/l, Sodium chloride - 8.6g/l Injectable solution 154,450 L.L
B05BB01 R-SOL G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 205,933 L.L
C01BC03 RYTMONORM B Propafenone HCl - 150mg 150mg Tablet, film coated 1,119,850 L.L
C01BC03 RYTMONORM B Propafenone HCl - 300mg 300mg Tablet, film coated 1,883,860 L.L
C01EB18 RANEXA B Ranolazine - 375mg 375mg Tablet, prolonged release 3,985,837 L.L
C01EB18 RANEXA B Ranolazine - 500mg 500mg Tablet, prolonged release 3,985,837 L.L
C01EB18 RANEXA B Ranolazine - 750mg 750mg Tablet, prolonged release 3,985,837 L.L
C03BA11 RAWEL SR G Indapamide - 1.5mg 1.5mg Tablet, prolonged release 362,837 L.L
C05AE01 RECTOGESIC G Glyceryl trinitrate - 0.2% w/w 0.2% w/w Ointment 2,553,301 L.L
C05CX REPARIL B Aescine - 20mg 20mg Tablet, sugar coated 510,660 L.L
    2
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026